efavirenz / Generic mfg. - LARVOL DELTA

Diagnosis, Clinical Phenotype, and Outcomes of Drug-Induced Liver Injury in Africa: A Systematic Review (ACG 2026) - "Time to onset varied greatly: days for NSAIDs and antibiotics, 2 to 8 weeks for anti-tuberculosis therapy (ATT), and up to 6 months for efavirenz-based antiretroviral therapy... We included 63 studies published between 1975-2025 across 20 African countries. The majority of studies came from South Africa (n=13), Cameroon (n=7), Ethiopia ( n=6), and Nigeria, (n=6). Most studies (80%) only used laboratory-based thresholds, mainly measuring ALT levels that ranged from â¥1.25à to â¥5à the upper limit of normal (ULN)."

Clinical • Review • Anorexia • Hepatology • Infectious Disease • Liver Failure • Respiratory Diseases • Tuberculosis

Understanding HIV epidemiology: a comprehensive analysis of demographic, clinical, and virological profiles of patients with HIV at a tertiary care center. (PubMed, IJID Reg) - "The most frequent ART regimen was tenofovir disoproxil fumarate/emtricitabine/efavirenz (28.6%)...This cohort reflects a predominantly male, heterosexually acquired HIV epidemic at this center, with a substantial burden of advanced disease at presentation and clinically relevant co-infection rates. Younger age at diagnosis was an independent risk factor for virological non-suppression, a finding that may support targeted retention and adherence interventions in younger PLWH."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

The Impact of Common Medications on Male Fertility: An Updated Systematic Review. (PubMed, Andrology) - "In this updated review, evidence-based recommendations for clinical management and for possible fertility preservation or contraception in men of reproductive age receiving common acute or chronic medical treatment are provided, with the goal of making these data more readily available to medical staff."

Journal • Review • Infertility

Dolutegravir Is Associated With Lower Odds of Gestational Diabetes Compared to Other Antiretroviral Therapy Regimens Among Pregnant Women in India: A Cross-Sectional Analysis. (PubMed, J Int AIDS Soc) - "Women on dolutegravir had lower odds of GDM compared to women taking other ART, despite greater weight gain. Ongoing studies are investigating the possible anti-inflammatory mechanisms."

Journal • Diabetes • Gestational Diabetes • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus • CD4

A Mechanistic In-silico Approach for Design and Evaluation of Novel (1H-indol-3-yl) Acetic Acid Analogues as Dual-action Anti-retroviral and Anti-bacterial Agents: A Foresight into Rational Drug Design Strategies. (PubMed, Curr Comput Aided Drug Des) - "Our comprehensive in silico research, comprising molecular docking, molecular dynamics simulations following MM-GBSA analysis, predictive ADMET analysis, trajectory analysis, and DFT studies, revealed strong binding affinity to amino acids, several hydrogen-bond interactions, structural stability, and drug-likeness properties, making compound 1m a lead pharmacophore in potential dual-action anti-retroviral and glucosamine-6-phosphate drug discovery."

Journal • Human Immunodeficiency Virus • Infectious Disease

Physiologically Based Pharmacokinetic Modeling to Assess Transporter-Mediated Drug-Drug Interactions in Support of Labeling Recommendations for Zavegepant Nasal Spray. (PubMed, Clin Pharmacol Ther) - "In clinical drug-drug interaction (DDI) studies, oral zavegepant exposure increased in the presence of multiple-dose (MD) rifampin or itraconazole; however, no interaction was observed between intranasal (IN) zavegepant and itraconazole...Predicted IN zavegepant exposure change with SD cyclosporine A was 1.58-fold (AUCR) when assuming 90:10 proportion for OATP1B3:NTCP contribution to hepatic uptake. CYP3A inducers, carbamazepine and efavirenz, were predicted to have minimal effect on IN zavegepant PK. Overall, PBPK modeling and observed PK data support that CYP3A/P-gp inhibitors and inducers do not produce clinically relevant modulation in IN zavegepant plasma exposure; however, OATP1B3/NTCP inhibitors can significantly increase IN zavegepant exposure, and coadministration should be avoided."

Journal • PK/PD data • CNS Disorders • Migraine • Pain • CYP3A4

Cost-effectiveness analysis of efavirenz versus ainuovirine in people living with HIV initiating first-line combination antiretroviral therapy. (PubMed, BMJ Open) - "Within the context of China's National Free Antiretroviral Treatment Programme, ANV-based regimens were cost-effective compared with EFV-based regimens among PLWH, with reduced adverse events and modest QALY gains at acceptable incremental costs. These findings support consideration of ANV-based regimens as an alternative option in future procurement and price negotiation decisions."

Clinical • HEOR • Journal • Human Immunodeficiency Virus • Infectious Disease

Recall and understanding of HIV-related counseling messages among progestin implant and injectable contraception users in Malawi. (PubMed, AIDS Care) - "We conducted a randomized clinical trial among Malawian women with and without HIV who were initiating the levonorgestrel (LNG) implant or depot medroxyprogesterone acetate (DMPA) injectable...In contrast, women more frequently recalled messages about potential reduced contraceptive effectiveness of the implant when used with ART. Women who continued their assigned contraceptive method were more likely to accurately recall counseling messages.Improved counseling strategies are needed to support clear communication and understanding of complex and evolving contraceptive and HIV-related risk information."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • Long-acting Reversible Contraceptives

Effects of Kudzu Root (Gegen) on Drug-Metabolizing Enzymes and Blood Clotting in Healthy Volunteers (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Chinese University of Hong Kong

Biomarker • New P1 trial • Thrombosis • CYP2C19 • CYP2C9 • CYP3A4

A scientometric study on research characteristics of HIV/AIDS involving the oral cavity with an implication for public health. (PubMed, J Dent Sci) - "The trend of drug aspect, e.g., antifungal agent, nystatin, and azole drugs before 2006 has changed to reverse transcriptase inhibitors efavirenz and lamivudine. Herein, we highlight the awareness of early diagnosis, and screening and testing of HIV, e.g., using saliva seems well-suited in dental setting. This study is the first scientometric analysis of HIV-related oral diseases with an implication for public health, underpinning that dentists and stomatologists can play active roles in providing early recognition and timely diagnosis of HIV/AIDS when it involved the oral cavity."

Journal • Candidiasis • Dental Disorders • Human Immunodeficiency Virus • Infectious Disease • Kaposi Sarcoma • Oncology • Periodontitis • Sarcoma • Solid Tumor

Efavirenz for the Treatment of Creutzfeldt-Jakob Disease (clinicaltrials.gov) - P3 | N=246 | Recruiting | Sponsor: Xuanwu Hospital, Beijing | Not yet recruiting ➔ Recruiting

Enrollment open

Therapeutic Failure or Success Risk Associated With the Dynamic of Immunological Parameters in People Living With HIV-1 on Antiretroviral Treatment in Benin. (PubMed, AIDS Res Treat) - "We observed low frequencies of CD4+ T, natural killer (NK), natural killer T (NKT) cells, classical monocytes, nonclassical monocytes, granulocytes, and high frequency of CD8+ T cells in all PLHIV-1 groups in treatment failure under dolutegravir (DTG) and efavirenz (EFV) regimens compared to control participants. Collectively, these results indicated that pro- and anti-inflammatory cytokines and immune cells could serve as prognostic factors for monitoring HIV-1 disease progression and response to ART. However, further studies with a larger sample size would be needed to confirm our data."

Journal • Human Immunodeficiency Virus • Infectious Disease • Oncology • CD4 • CD8 • IFNG • IL13 • IL4 • IL5 • IL6 • IL7 • TNFA

Rezvilutamide combined with ADT in an HIV-positive patient with high-volume mHSPC on efavirenz-based antiretroviral therapy: a case report. (PubMed, Front Oncol) - "This case directly addresses the controversies and challenges regarding the use of intensified therapy in patients with comorbidities in current clinical practice, suggesting that key drug-drug interaction barriers may be manageable through personalized strategies and proactive management. This case provides a practical reference for implementing guideline-recommended treatment intensification principles in similar complex clinical scenarios, offering clinically relevant insights."

Journal • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Human Immunodeficiency Virus • Infectious Disease • Oncology • Prostate Cancer • Solid Tumor • CYP3A4

Model-based clinical utility of pharmacogenetic testing and its potential population impact on the use of essential medicines in Zimbabwe. (PubMed, Front Pharmacol) - "Lower NNG values were observed for UGT1A1-atazanavir (5), UGT1A1-irinotecan (9), CYP2B6-efavirenz (26), and CYP2C9-phenytoin (25), whereas 61% of gene-drug pairs had NNG values > 1,000 compared with 47% in the Dutch population. Many essential medicines in Zimbabwe have actionable pharmacogenomic biomarkers, but gaps in local genomic guidance remain. Strengthening local evidence generation and PGx implementation is essential."

Biomarker • Journal • CYP2C9 • UGT1A1

Clinical and demographic characteristics of adult patients experiencing virologic failure on antiretroviral therapy in the Blouberg sub-district, South Africa. (PubMed, BMC Infect Dis) - "Patients experiencing virologic failure were predominantly female, initiated ART with low CD4 counts, and commonly received efavirenz-based regimens. The findings highlight the importance of early HIV diagnosis, strengthened adherence support, timely viral load monitoring, and optimization of ART regimens to improve treatment outcomes in rural settings. Targeted adherence interventions and earlier ART initiation strategies are needed to improve viral suppression outcomes in rural settings."

Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • CD4

HIV therapy: Synthetic and computational evaluation of ring-modified Efavirenz analogs | Poster Board #1798 (ACS-Fall 2026) - "While dolutegravir-based regimens are widely used, EFV remains clinically relevant in many developing countries. Computational results were used to assess binding orientation and predicted inhibitory activity relative to EFV. Together, this synthetic and computational approach aims to identify structurally accessible EFV analogs that retain antiviral activity while enhancing chemical stability, improving synthetic feasibility, and develop more affordable treatment options."

Human Immunodeficiency Virus • Infectious Disease

HIV therapy: Synthetic and computational evaluation of ring-modified Efavirenz analogs | Poster Board #1603 (ACS-Fall 2026) - "While dolutegravir-based regimens are widely used, EFV remains clinically relevant in many developing countries. Computational results were used to assess binding orientation and predicted inhibitory activity relative to EFV. Together, this synthetic and computational approach aims to identify structurally accessible EFV analogs that retain antiviral activity while enhancing chemical stability, improving synthetic feasibility, and develop more affordable treatment options."

Human Immunodeficiency Virus • Infectious Disease

Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Indiana University | Trial completion date: Dec 2026 ➔ May 2027 | Trial primary completion date: Aug 2026 ➔ May 2027

Trial completion date • Trial primary completion date

Association between initial antiretroviral therapy regimens and virological outcomes in HIV-infected individuals in Taizhou, Zhejiang Province, 2006-2025 (PubMed, Zhonghua Liu Xing Bing Xue Za Zhi) - "Apart from the two nucleotide reverse transcriptase inhibitors backbone drugs, the proportions of selecting efavirenz (EFV), nevirapine (NVP), lopinavir/ritonavir (LPV/r), dolutegravir (DTG), and other drugs as the third drug were 80.22% (2 976/3 710), 15.12% (561/3 710), 1.32% (49/3 710), 1.08% (40/3 710), and 2.26% (84/3 710) respectively-205 individuals (5.53%) with virological failure. After adjusting for the educational level of the study subjects, initial CD4+T lymphocyte counts, initial viral load, time interval from diagnosis to ART initiation, and the year of ART initiation, the risk of virological failure in the NVP group was 4.93 times that of the [integrase inhibitors/protease inhibitors(INSTI/PI)] group (95%CI: 1.73-14.05), and 2.72 times that of the EFV group (95%CI: 1.92-3.85). Among HIV-infected individuals in Taizhou who received NVP-based initial ART regimens between 2006 and 2025, the risk of virological failure was higher than among those who..."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

Analysis of HIV Drug Resistance Mutations Along With Treatment Outcomes of Efavirenz-Based Regimens in Patients With V179D/E Mutations in Guangzhou, China. (PubMed, Can J Infect Dis Med Microbiol) - "The prevalence of DRMs in newly diagnosed HIV-1-infected individuals in Guangzhou associated with NNRTIs is 22.16%, primarily driven by the V179D/E mutation. EFV-based treatments were associated with higher cumulative virological failure rates in patients with V179D/E mutation."

Journal • Human Immunodeficiency Virus • Infectious Disease

Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Active, not recruiting ➔ Completed

Trial completion • Pain

HIV care interruptions during the first year of antiretroviral therapy among adolescents and young adults living with HIV aged 15-24 years in Khayelitsha, South Africa. (PubMed, J Acquir Immune Defic Syndr) - "Early HIV care interruption was common, particularly during COVID-19. Dolutegravir was associated with improved retention, yet substantial early interruptions persisted, highlighting the need for intensified youth-focused support following ART initiation."

Journal • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease

National cross-sectional survey on acquired HIV drug resistance in Haiti in 2023: warnings resistance to dolutegravir (AIDS 2026) - "3.77% of HIVs were resistant to dolutegravir and bictegravir, 4.4% to cabotegravir, 4.72% to raltegravir, and 5.03% to elvitegravir. Additionally, 15.19% of the viral strains were resistant to abacavir, 13.92% to lamivudine and emtricitabine, 6.65% to zidovudine, 8.23% to stavudine and didanosine, and 4.13% to tenofovir...Furthermore, some HIVs strains developed resistance against efavirenz (49.37%), nevirapine (50%), Rilpivirine (20.25%), Etravirine (12.66%), and doravirine (3.61%). Finally, HIV genome resistance was 0.63% against atazanavir/ritonavir and indinavir/ritonavir, 0.95% against lopinavir/ritonavir and 0.32% against darunavir/ritonavir. HIV acquired pharmacoresistance is moderate in Haiti and requires innovating adapted strategy for preventing its development, its transmission, and for protecting PLHIV health, while emphasizing on children and male individuals."

Human Immunodeficiency Virus • Infectious Disease • Respiratory Diseases

Incidence of mutational patterns affecting doravirine or/and rilpivirine in people living with HIV and previous failure with NNRTIs efavirenz or nevirapine (AIDS 2026) - "BACKGROUND: The growing use of new non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as doravirine (DOR) or long-acting rilpivirine (RPV) makes necessary to evaluate the impact of previous failure to NNRTIs. Our results confirm that doravirine resistance in NNRTI-failing PLWH is lower than resistance to other NNRTIs currently used. However, these data suggest considering carefully genotypic resistance test results before the use of RPV or DOR in the clinical setting in those PLWH with previous failure to NNRTIs."

Human Immunodeficiency Virus • Infectious Disease • CD4

Resistance to etravirine and doravine in experienced PLHIV in Mexico. Impact on salvage treatment (AIDS 2026) - "BACKGROUND: Doravirine (DOR) and Etravirine (ETV) are the only NNRTIs indicated in people living with HIV (PLHIV) after virologic failure (VF) to first-generation NNRTIs as Efavirenz and Nevirapine. In our study, resistance to ETR in adult PLHIV who experienced at least two treatment failures in Mexico, was lower than to DOR. HLR was uncommon specially with respect to total sample, but higher (almost double) to DOR. Resistance prevalence could be higher, as most of the genotypes were performed without the NNRTI drug pressure."

Human Immunodeficiency Virus • Infectious Disease